The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSensetm, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data ...

For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic ...

DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...